Imugene initiates first patient dosage in Phase 1 onCARlytics trial targeting solid cancers.
Imugene, an Australian biotech company, has initiated the first patient dosage in the IV arm of its Phase 1 onCARlytics trial. The trial targets solid cancers and utilizes an IV infusion combination. This marks an important milestone in the development of cancer treatment options and further solidifies Imugene's position in the cancer research sector.
June 24, 2024
4 Articles